Hemoperfusion Cartridges to Record Rising Demand Due to Growing Blood Purification Cases

The coming years are expected to record a considerable demand for hemoperfusion cartridges. This can be credited to an increase in the number of blood purification cases. This is on account of escalating cases in metabolic and autoimmune health disorders. Additional factors favoring product deployment include the improvement in bio separation techniques such as dialysis, absorption, and filtration.

According to Business Research Insights, the global hemoperfusion cartridge market size was USD 669.9 million in 2022. The industry is projected to reach USD 1556.8 million by 2028, exhibiting a CAGR of 15.1% from 2022 to 2028.

The market growth can be attributed to the soaring investments and technological advancements for supporting a series of applications in North America. The regional industry share is expected to record appreciable expansion over the forecast period.

COVID-19 Impact: A Brief About the Pandemic Period

The pandemic period led to an increase in the launch of various research activities. Several organizations are conducting experiments and releasing their findings for various cases.

One such study focused on the capability of hemoperfusion for the removal of harmful substances. The procedure was found to be an effective medium for the removal of cytokines and the reduction of inflammatory effects.

Endotoxemia and Polymyxin B Hemoperfusion During COVID-19 Times

According to research, coronavirus enters through ACE-2 (angiotensin-converting enzyme-2) receptor, which is expressed in enterocytes in the colon and ileum. This could lead to the translocation of endotoxin from the intestinal tract which is likely to exacerbate the severity of COVID-19.

The removal of endotoxin is critical during antibiotic therapy for the prevention of tissue death and endotoxic shock. The shock constitutes an emergency condition where prompt and appropriate administration of antimicrobial therapy could enhance the survival chances of a patient. The removal of endotoxin can be performed by deploying polymyxin B hemoperfusion (PMX-HP). PMX-HP is not only an immunomodulatory device but also allows the removal of endotoxin.

What Steps Are Key Market Players Taking to Strengthen Industry Position

Leading industry participants are entering a series of strategic initiatives such as mergers, acquisitions, and others for the consolidation of industry position. Some of the other initiatives comprise the formation of alliances, partnership agreements, collaborations, and others. Furthermore, numerous companies are participating in trade conferences and fairs for enhancing their business prospects.

Mentioned below is the list of major players in the market:

• Baihe Medical (China)
• Asahi Kasei Corporation (Japan)
• Jafron Biomedical (China)
• Kaneka Pharma (Japan)
• Kangbeir Medical Device (China)
• Toray Medical (Japan)
• Biosun Corporation (U.S.)
• Cytosorbents Corporation (U.S.)

Besides, these companies are developing and launching various products for strengthening their market position. Considering an instance, in September 2021, Jafron Biomedical secured authorization from Health Canada for the import and sale of its HA330 and HA380 Disposable Hemoperfusion Cartridges.

The solutions have been deployed in extracorporeal circulation therapies for coronavirus patients with multiple organ dysfunction or failure. The procedures are carried out by the adsorption of inflammatory cytokine via the advanced double cross-linked resin sorbent, as per the intended usage approved by Health Canada.

Prominent Industry Developments:

Over the recent years, the hemoperfusion cartridge industry recorded a series of developments. These include:

• In October 2022, Spectral Medical Inc., offered a clinical trial update on Tigris, which assessed the usage of Polymyxin B hemoperfusion in a randomized controlled trial of adults treated for septic shock and endotoxemia. The late stage theranostic company is focused on advancing therapeutic options for septic shock and sepsis. Further, it is centered on commercializing a new platform targeting the renal replacement therapy market.
• In July 2022, a therapeutic hemoperfusion device was launched for the removal of endotoxin from the bloodstream. The device was guided by the only FDA-cleared diagnostic assay for the risk of sepsis development. Of the various strategies adopted for the elimination of endotoxin, Polymyxin-B hemoperfusion has been the most effective.

Way Ahead

In the years to come, hemoperfusion cartridges are estimated to gain remarkable traction. This is on account of the surging demand for hemoperfusion cartridge from the healthcare sector for the removal of poison and toxins from blood. The increasing popularity can be further attributed to the new coating technology and developments in production.